Skip to main content

Table 1 Patient characteristics

From: Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions

  No. of patients (n = 45)
No. %
Age at diagnosis, years
 Median 60 (range: 32 to 81)
Sex
 Male 30   66.7
 Female 15   33.3
Primary tumor location
 Gastroesophageal junction/fundus 4   8.9
 Body 8   17.8
 Antrum 22   48.9
 Diffuse 11   24.4
Primary tumor tissue for HER2 assessment
 Endoscopic biopsy 38   84.4
 Surgical resection 7   15.6
Lauren classification
 Intestinal 21   46.7
 Diffuse 23   51.1
 Mixed 1   2.2
WHO classification
 Tubular adenocarcinoma
  Well differentiated 1   2.2
  Moderately differentiated 18   40.0
  Poorly differentiated 13   28.9
 Mucinous carcinoma 1   2.2
 Poorly cohesive carcinoma 11   24.5
 Mixed adenocarcinoma 1   2.2
Cell block of malignant effusion (n = 71)
 Sample type    
  Ascitic fluid 64   90.1
  Pleural fluid 7   9.9
 Cellularity    
  High (> 10% tumor cells) 40   56.3
  Low (≤10% tumor cells) 31   43.7
 Time of effusion sample collection
  At the diagnosis of metastatic disease before chemotherapy 23   32.4
  During or after palliative chemotherapy 48   67.6
  1. HER2, human epidermal growth factor receptor 2; WHO, World Health Organization